Nomura retains Buy on Gland Pharma, raises target to Rs3,750
Nomura kept its Buy rating on Gland Pharma and lifted its target price to Rs3,750 from Rs3,330, citing a shift toward a more CDMO-centric strategy and an expected ~20% guided revenue CAGR supported by CDMO, biologics and in-licensing.